Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002080
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: April 2003
  Purpose

Primary: To provide rifabutin to HIV positive patients in an attempt to prevent or delay Mycobacterium avium Complex (MAC) infection by a daily dose of rifabutin.

Secondary: To further characterize the safety of rifabutin monotherapy in preventing or delaying MAC bacteremia in HIV positive patients with CD4 counts = or < 200.


Condition Intervention
Mycobacterium Avium-intracellulare Infection
HIV Infections
Drug: Rifabutin

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Resource links provided by NLM:


Further study details as provided by NIH AIDS Clinical Trials Information Service:

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Any medication with the exception of other investigational drugs not available under a treatment IND, expanded access, or parallel track program.

Patients must have:

  • Confirmed HIV infection.
  • CD4 cell counts <= 200 cells/mm3.
  • No evidence of disseminated MAC disease.
  • Informed consent of parent or guardian if 12 to < 18 years of age.

NOTE:

  • Pregnant females may be eligible. There are no studies of the safety or efficacy of rifabutin in pregnant women. Rifabutin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In addition, a risk/benefit decision should consider the likelihood of a woman's developing MAC if she does not receive prophylaxis. The risk of developing MAC rises substantially for women with CD4 counts less than 100, although it can also develop in women with higher CD4 counts. Women of reproductive potential who are not pregnant must use contraception. They are encouraged to use means other than oral contraceptives.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

  • Known hypersensitivity to rifabutin, rifampin, or other rifamycins.
  • Current infection due to MAC or other mycobacterial disease, or complaints consistent with tuberculosis.

Concurrent Medication:

Excluded:

  • Other investigational drugs with the exception of those available under a treatment IND, expanded access, or parallel track program. (Licensed products prescribed for unlabeled indications are not considered investigational.)

Patients with the following prior conditions are excluded:

Prior infection due to MAC or other mycobacterial disease or complaints consistent with tuberculosis.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002080

Locations
United States, Pennsylvania
PACT
Saint Davids, Pennsylvania, United States, 19087
Sponsors and Collaborators
Pharmacia
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00002080     History of Changes
Other Study ID Numbers: 109A, 087085-999
Study First Received: November 2, 1999
Last Updated: June 23, 2005
Health Authority: United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:
Rifabutin
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Mycobacterium avium Complex
Bacteremia

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
HIV Seropositivity
Rifabutin
Bacteremia
Communicable Diseases
Infection
Mycobacterium Infections
Mycobacterium avium-intracellulare Infection
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Immune System Diseases
Immunologic Deficiency Syndromes
Inflammation
Lentivirus Infections
Mycobacterium Infections, Nontuberculous
Pathologic Processes
RNA Virus Infections
Retroviridae Infections
Sepsis
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Systemic Inflammatory Response Syndrome
Virus Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antitubercular
Antitubercular Agents

ClinicalTrials.gov processed this record on November 27, 2014